Chen Kun, Jiang Kehua, Tang Lannan, Chen Xiaolong, Hu Jianxin, Sun Fa
NHC Key Laboratory of Pulmonary Immune-Related Diseases, Guizhou Provincial People's Hospital, Guiyang, China.
Department of Urology, Guizhou Provincial People's Hospital, Guiyang, China.
Front Oncol. 2021 May 12;11:647110. doi: 10.3389/fonc.2021.647110. eCollection 2021.
The overall aging of the world population has contributed to the continuous upward trend in the incidence of prostate cancer (PC). Trials on PC therapy have been extensively performed, but no study has analyzed the overall trends and characteristics of these trials, especially for those carried out in China. This study aimed to provide insights on the future direction of drug development in PC, thus supplying essential supportive data for stakeholders, including researchers, patients, investors, clinicians, and pharmaceutical industry. The details of the clinical trials of drug therapies for PC during January 1, 2010, to January 1, 2020, were collected from Pharmaprojects. A total of 463 clinical trials on different therapies with 132 different drugs were completed. The long-acting endocrine therapy with few side effects, radiotherapy combined with immune checkpoint inhibitors, gene-targeted chemotherapeutics, and novel immunotherapeutic products changed the concept of PC treatment. In mainland China, 31 trials with 19 drugs have been completed in the 10 assessment years. China has initiated a few trials investigating a limited number of drug targets, centered in a markedly uneven geographical distribution of leading clinical trial units; hence, the development of PC drugs has a long way to go. Given the large patient pool, China deserves widespread attention for PC drug research and development. These findings might have a significant impact on scientific research and industrial investment.
全球人口的总体老龄化导致前列腺癌（PC）发病率持续呈上升趋势。针对PC治疗的试验已广泛开展，但尚无研究分析这些试验的总体趋势和特点，尤其是在中国开展的试验。本研究旨在为PC药物研发的未来方向提供见解，从而为包括研究人员、患者、投资者、临床医生和制药行业在内的利益相关者提供重要的支持数据。从Pharmaprojects收集了2010年1月1日至2020年1月1日期间PC药物治疗的临床试验详细信息。共完成了463项针对不同疗法、使用132种不同药物的临床试验。副作用较少的长效内分泌疗法、放疗联合免疫检查点抑制剂、基因靶向化疗药物以及新型免疫治疗产品改变了PC治疗的理念。在中国大陆，在这10个评估年份中完成了31项使用19种药物的试验。中国开展了一些针对有限数量药物靶点的试验，主要临床试验单位的地理分布明显不均衡；因此，PC药物的研发还有很长的路要走。鉴于庞大的患者群体，中国的PC药物研发值得广泛关注。这些发现可能对科研和产业投资产生重大影响。
